News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx to Present at 2016 BIO International Convention
FREMONT, Calif. , June 3, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Jeremy S. Caldwell , Ph.D., Executive Vice President and Chief Scientific Officer, will present an
View HTML
Toggle Summary Ardelyx Reports First Quarter 2016 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET
View HTML
Toggle Summary Ardelyx to Report First Quarter 2016 Financial Results on May 9, 2016
FREMONT, Calif. , May 2, 2016 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report first quarter 2016 financial results Monday, May 9, 2016 after the close of the
View HTML
Toggle Summary Ardelyx Reports Fourth Quarter and Full-Year 2015 Financial Results
Three Late-Stage Clinical Trials for Tenapanor Initiated in 4Q2015RDX022 PD Study Results Support Pivotal Phase 3 Clinical Trial Plans for Hyperkalemia in 2H2016Conference Call and Webcast Today at 8:00 a.m. ET
View HTML
Toggle Summary Ardelyx to Report Fourth Quarter and Full Year 2015 Financial Results on March 4th, 2016
FREMONT, Calif. , Feb. 25, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2015 ,
View HTML
Toggle Summary Ardelyx to Present at the 2016 Leerink Partners Global Healthcare Conference
FREMONT, Calif. , Feb. 2, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and renal diseases, today announced that Mike Raab , President and Chief Executive Officer, and David Rosenbaum , Ph.D., Senior Vice President of
View HTML
Toggle Summary Ardelyx Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
FREMONT, Calif. , Jan. 13, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the completion of its previously announced underwritten public offering of 8,625,000 shares of its common
View HTML
Toggle Summary Ardelyx Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , Jan. 7, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , Jan. 6, 2016 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has commenced an underwritten public offering of up to $75,000,000 of shares of its common stock.
View HTML
Toggle Summary Ardelyx Reports Positive Clinical Results of RDX022 for the Treatment of Hyperkalemia
RDX022, Ardelyx's proprietary potassium binder, demonstrates clinically relevant fecal potassium binding in a pharmacodynamic study in healthy volunteers, supporting Phase 3 clinical plansInitiation of a Phase 3 clinical program with RDX022 is expected in 2H2016Conference call and webcast today at 8:00am ET
View HTML